These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

632 related articles for article (PubMed ID: 19135797)

  • 21. Analgesic effects of capsazepine and resiniferatoxin on bone cancer pain in mice.
    Menéndez L; Juárez L; García E; García-Suárez O; Hidalgo A; Baamonde A
    Neurosci Lett; 2006 Jan; 393(1):70-3. PubMed ID: 16243435
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 7-tert-Butyl-6-(4-chloro-phenyl)-2-thioxo-2,3-dihydro-1H-pyrido[2,3-d]pyrimidin-4-one, a classic polymodal inhibitor of transient receptor potential vanilloid type 1 with a reduced liability for hyperthermia, is analgesic and ameliorates visceral hypersensitivity.
    Nash MS; McIntyre P; Groarke A; Lilley E; Culshaw A; Hallett A; Panesar M; Fox A; Bevan S
    J Pharmacol Exp Ther; 2012 Aug; 342(2):389-98. PubMed ID: 22566669
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potentiation of analgesic efficacy but not side effects: co-administration of an α4β2 neuronal nicotinic acetylcholine receptor agonist and its positive allosteric modulator in experimental models of pain in rats.
    Zhu CZ; Chin CL; Rustay NR; Zhong C; Mikusa J; Chandran P; Salyers A; Gomez E; Simler G; Lewis LG; Gauvin D; Baker S; Pai M; Tovcimak A; Brown J; Komater V; Fox GB; Decker MW; Jacobson PB; Gopalakrishnan M; Lee CH; Honore P
    Biochem Pharmacol; 2011 Oct; 82(8):967-76. PubMed ID: 21620806
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transient receptor potential vanilloid 1 mediates hyperalgesia and is up-regulated in rats with chronic pancreatitis.
    Xu GY; Winston JH; Shenoy M; Yin H; Pendyala S; Pasricha PJ
    Gastroenterology; 2007 Oct; 133(4):1282-92. PubMed ID: 17698068
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TRPV1 receptors in the CNS play a key role in broad-spectrum analgesia of TRPV1 antagonists.
    Cui M; Honore P; Zhong C; Gauvin D; Mikusa J; Hernandez G; Chandran P; Gomtsyan A; Brown B; Bayburt EK; Marsh K; Bianchi B; McDonald H; Niforatos W; Neelands TR; Moreland RB; Decker MW; Lee CH; Sullivan JP; Faltynek CR
    J Neurosci; 2006 Sep; 26(37):9385-93. PubMed ID: 16971522
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Involvement of transient receptor potential vanilloid 1 receptors in protease-activated receptor-2-induced joint inflammation and nociception.
    Helyes Z; Sándor K; Borbély E; Tékus V; Pintér E; Elekes K; Tóth DM; Szolcsányi J; McDougall JJ
    Eur J Pain; 2010 Apr; 14(4):351-8. PubMed ID: 19683949
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic potential of vanilloid receptor TRPV1 agonists and antagonists as analgesics: Recent advances and setbacks.
    Wong GY; Gavva NR
    Brain Res Rev; 2009 Apr; 60(1):267-77. PubMed ID: 19150372
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Heat and mechanical hyperalgesia in mice model of cancer pain.
    Asai H; Ozaki N; Shinoda M; Nagamine K; Tohnai I; Ueda M; Sugiura Y
    Pain; 2005 Sep; 117(1-2):19-29. PubMed ID: 16043290
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Involvement of capsaicin-sensitive afferents and the Transient Receptor Potential Vanilloid 1 Receptor in xylene-induced nocifensive behaviour and inflammation in the mouse.
    Sándor K; Helyes Z; Elekes K; Szolcsányi J
    Neurosci Lett; 2009 Feb; 451(3):204-7. PubMed ID: 19159661
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin- 3-yl)pyrido[2,3-d]pyrimidine), a novel orally effective adenosine kinase inhibitor with analgesic and anti-inflammatory properties. II. In vivo characterization in the rat.
    Kowaluk EA; Mikusa J; Wismer CT; Zhu CZ; Schweitzer E; Lynch JJ; Lee CH; Jiang M; Bhagwat SS; Gomtsyan A; McKie J; Cox BF; Polakowski J; Reinhart G; Williams M; Jarvis MF
    J Pharmacol Exp Ther; 2000 Dec; 295(3):1165-74. PubMed ID: 11082454
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Participation of the spinal TRPV1 receptors in formalin-evoked pain transduction: a study using a selective TRPV1 antagonist, iodo-resiniferatoxin.
    Kanai Y; Hara T; Imai A
    J Pharm Pharmacol; 2006 Apr; 58(4):489-93. PubMed ID: 16597366
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Systemic and site-specific effects of A-425619, a selective TRPV1 receptor antagonist, on wide dynamic range neurons in CFA-treated and uninjured rats.
    McGaraughty S; Chu KL; Faltynek CR; Jarvis MF
    J Neurophysiol; 2006 Jan; 95(1):18-25. PubMed ID: 16162831
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A role for vanilloid receptor 1 (TRPV1) and endocannabinnoid signalling in the regulation of spontaneous and L-DOPA induced locomotion in normal and reserpine-treated rats.
    Lee J; Di Marzo V; Brotchie JM
    Neuropharmacology; 2006 Sep; 51(3):557-65. PubMed ID: 16806299
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacology of modality-specific transient receptor potential vanilloid-1 antagonists that do not alter body temperature.
    Reilly RM; McDonald HA; Puttfarcken PS; Joshi SK; Lewis L; Pai M; Franklin PH; Segreti JA; Neelands TR; Han P; Chen J; Mantyh PW; Ghilardi JR; Turner TM; Voight EA; Daanen JF; Schmidt RG; Gomtsyan A; Kort ME; Faltynek CR; Kym PR
    J Pharmacol Exp Ther; 2012 Aug; 342(2):416-28. PubMed ID: 22570364
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine]: a novel, orally effective antinociceptive agent acting via neuronal nicotinic acetylcholine receptors: II. In vivo characterization.
    Bannon AW; Decker MW; Curzon P; Buckley MJ; Kim DJ; Radek RJ; Lynch JK; Wasicak JT; Lin NH; Arnold WH; Holladay MW; Williams M; Arneric SP
    J Pharmacol Exp Ther; 1998 May; 285(2):787-94. PubMed ID: 9580627
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of A-425619 at native TRPV1 receptors: a comparison between dorsal root ganglia and trigeminal ganglia.
    McDonald HA; Neelands TR; Kort M; Han P; Vos MH; Faltynek CR; Moreland RB; Puttfarcken PS
    Eur J Pharmacol; 2008 Oct; 596(1-3):62-9. PubMed ID: 18755179
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of antinociceptive actions of standard analgesics in attenuating capsaicin and nerve-injury-induced mechanical hypersensitivity.
    Joshi SK; Hernandez G; Mikusa JP; Zhu CZ; Zhong C; Salyers A; Wismer CT; Chandran P; Decker MW; Honore P
    Neuroscience; 2006 Dec; 143(2):587-96. PubMed ID: 16962719
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Silencing of vanilloid receptor TRPV1 by RNAi reduces neuropathic and visceral pain in vivo.
    Christoph T; Grünweller A; Mika J; Schäfer MK; Wade EJ; Weihe E; Erdmann VA; Frank R; Gillen C; Kurreck J
    Biochem Biophys Res Commun; 2006 Nov; 350(1):238-43. PubMed ID: 16996476
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Capsaicin (TRPV1 Agonist) therapy for pain relief: farewell or revival?
    Knotkova H; Pappagallo M; Szallasi A
    Clin J Pain; 2008 Feb; 24(2):142-54. PubMed ID: 18209521
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TRPV1: a therapeutic target for novel analgesic drugs?
    Szallasi A; Cruz F; Geppetti P
    Trends Mol Med; 2006 Nov; 12(11):545-54. PubMed ID: 16996800
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.